Answers are grounded in this paper and cite their sources.
Purpose: The study purpose was to evaluate real-world data on routes of administration (ROAs) employed for nonmedical use (NMU) of XTAMPZA ER compared to other oxycodone extended-release (ER) and oxycodone immediate-release (IR) formulations in a population of adults assessed for substance use. Patients and Methods: A cross-sectional observational study was conducted among adults assessed for substance use and treatment planning using the Addiction Severity Index-Multimedia Version (ASI-MV ® ) from July 2016 through December 2023. Demographic and substance use history data were summarized to characterize the sample. The primary outcome measure was the prevalence of past 30-day non-oral NMU, assessed first by using Pearson’s chi-square to test differences in prevalence, then by calculating the proportional reporting ratios (PRR) to determine if specific non-oral ROAs were more or less likely to be used for XTAMPZA ER NMU versus comparators. Results: The prevalence of non-oral ROA cases was significantly higher among other oxycodone ER cases (2221/4935, 45.0%) and oxycodone IR cases (10,598/20,394, 52.0%) compared to XTAMPZA ER cases (31/141, 22.0%)(X 2 =29.43, p< 0.0001 and X 2 =50.41, p< 0.0001, respectively). Compared to other oxycodone ER, XTAMPZA ER had a 33% lower risk of snorting (PRR: 0.67, 95% CI: 0.47, 0.95) and a 63% lower risk of injecting (PRR: 0.37, 95% CI: 0.19, 0.71). Compared to oxycodone IR, XTAMPZA ER had a 46% lower risk of snorting (PRR: 0.54, 95% CI: 0.38, 0.77) and a 66% lower risk of injecting (PRR: 0.44, 95% CI: 0.23, 0.86). Conclusion: Opioid medications can provide valuable patient benefits with risks best mitigated by using formulations associated with lower likelihood of NMU, particularly via higher-risk non-oral ROAs. These study findings suggest that XTAMPZA ER has a lower risk of NMU via non-oral ROA compared to other oxycodone ER and oxycodone IR products in an enriched population of substance users.
No takes yet. Share an insight, caveat, or question.
Green et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: